T0903131 (INT131) besylate

INT131 besylate · InteKrin Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for T0903131 (INT131) besylate, covering 2022-10-19 to 2022-10-19. Get the full timeline:

Most recent: Clinical Trial Update: A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus [Phase 2]